Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 3, Pages e1398874
Publisher
Informa UK Limited
Online
2017-11-03
DOI
10.1080/2162402x.2017.1398874
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients
- (2017) Lysanne A. Lievense et al. LUNG CANCER
- Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer
- (2017) Dennis O. Adeegbe et al. Cancer Discovery
- Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
- (2016) Ramiro Vázquez et al. INTERNATIONAL JOURNAL OF CANCER
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Searching for targets for the systemic therapy of mesothelioma
- (2015) R. A. Stahel et al. ANNALS OF ONCOLOGY
- Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies
- (2015) J. Remon et al. CANCER TREATMENT REVIEWS
- Targeting immune checkpoints: New opportunity for mesothelioma treatment?
- (2015) Elly Marcq et al. CANCER TREATMENT REVIEWS
- Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
- (2015) Malik Hamaidia et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells
- (2015) Zhe Yu et al. Oncotarget
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
- (2015) Stuart Gallagher et al. Cancers
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
- (2015) Iris Chiara Salaroglio et al. Oncotarget
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
- (2014) G. Guo et al. CANCER RESEARCH
- Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
- (2014) Aurélien de Reyniès et al. CLINICAL CANCER RESEARCH
- Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
- (2014) Alison M. McDonnell et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
- (2014) Stuart J. Gallagher et al. Pigment Cell & Melanoma Research
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- The role of epigenetics in malignant pleural mesothelioma
- (2013) Fabian Vandermeers et al. LUNG CANCER
- Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
- (2013) Chiara Riganti et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies
- (2012) Valerio Izzi et al. CANCER LETTERS
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More